Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

Cancer

Volumn 73, Issue 2, 1994, Pages 432-436

  Wu, Li‐Teh ^a   Averbuch, Steven D ^b   Ball, Douglas W ^c   De Bustros, Andree ^c   Baylin, Stephen B ^c   McGuire, William P ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

calcitonin; carcinoembryonic antigen; cyclophosphamide; dacarbazine; medullary thyroid carcinoma; neuroendocrine cancer; vincristine

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; TUMOR MARKER; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; CYCLOPHOSPHAMIDE; DACARBAZINE; FEMALE; HUMAN; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.; THYROID NEOPLASMS; VINCRISTINE;

EID: 0028155972     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K     Document Type: Article

References (33)

1. Neoplasms of the neuroendocrine system
2. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients
3. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy
4. Biology and management of medullary thyroid carcinoma of the parafollicular cells. In: Robbins J, moderator. Thyroid cancer: a lethal endocrine neoplasm
5. Multiple endocrine neoplasia type 2b: the most aggressive form of medullary thyroid cancer
6. Chemotherapy for advanced thyroid cancer
7. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine
8. Effects de l'administration sous cutanee de sandostatine (SMS 201.995) en sous catane dans 18 cas de cancer medullaire du corps thyroide
9. The prognostic and biologic significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L‐Dopa decarboxylase, and histaminase
10. The value of calcitonin and carcinoembryonic antigen in the treatment and management of non‐familial medullary thyroid carcinoma
11. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid cancer
12. Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, histology, immunocytochemistry and DNA content
13. The role radiation therapy in medullary carcinoma of the thyroid
14. Adriamycin (NSC‐123127): therapy in thyroid carcinoma
15. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
16. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy
17. Medullary thyroid carcinoma: prognostic factors and treatment
18. Management of medullary carcinoma of the thyroid
19. Long‐term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide
20. The diffuse neuroendocrine system and the APUD concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands
21. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes
22. Streptozocin‐doxorubicin, streptozocin‐fluorouracil, or chlorozotocin in the treatment of advanced islet‐cell carcinoma
23. Streptozotocin and adriamycin in the treatment of APUD tumors (carcinoid, islet cell and medullary carcinoma of the thyroid)
24. Phase 2 evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group trial
25. Doxorubicin plus cisplatin in the treatment of apudomas
26. Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid
27. Therapy of malignant APUD cell tumors
28. Metastatic medullary thyroid carcinoma
29. Chemotherapy for thyroid cancer
30. Phase 2 trial of VP‐16 in Apudomas
31. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdr1 gene and low proliferation fraction
32. Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa p‐glycoprotein
33. Multiple endocrine neoplasia